Kane Biotech Inc. announced that it has filed a patent on its revyveTM Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510 (k) cleared revyveTM Antimicrobial Wound Gel, and will be introducing it at the Boswick Burn and Wound Care Symposium.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.135 CAD | +3.85% | +12.50% | +68.75% |
1st Jan change | Capi. | |
---|---|---|
+68.75% | 12.52M | |
+49.68% | 56.95B | |
+39.98% | 40.26B | |
-7.46% | 39.32B | |
-4.42% | 28.37B | |
+11.85% | 26.45B | |
-18.17% | 19.41B | |
+29.07% | 12.54B | |
+25.71% | 12.21B | |
-1.36% | 12.15B |
- Stock Market
- Equities
- KNE Stock
- News Kane Biotech Inc.
- Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray